Calcitonin gene related peptide receptor antagonists
申请人:——
公开号:US20040204397A1
公开(公告)日:2004-10-14
The present invention relates to compounds of Formula (I)
1
as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
[EN] CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DU PEPTIDE RELIE AU GENE DE LA CALCITONINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2003104236A1
公开(公告)日:2003-12-18
The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related
peptide receptors ("CGRP-receptor"), pharmaceutical compositions
comprising them, methods for identifying them, methods of treatment using them
and their use in therapy for treatment of neurogenic vasodilation, neurogenic
inflammation, migraine and other headaches, thermal injury, circulatory shock,
flushing associated with menopause, airway inflammatory diseases, such as
asthma and chronic obstructive pulmonary disease (COPD), and other conditions the
treatment of which can be effected by the antagonism of CGRP-receptors.
The present invention relates to compounds of Formula (I)
as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I)
The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R
1
, R
2
, R
3
, R
4
, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.